Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab.

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab.

Publication date: Sep 12, 2019

Immune checkpoint inhibition has dramatically transformed the treatment of malignant melanoma. With increasing use, their unique spectrum of immune-mediated toxicity has become apparent.

We describe a case of sequential immune-related adverse events (irAEs) in a patient with metastatic melanoma treated with single-agent anti-programmed cell death-1 (PD-1) therapy, pembrolizumab. Although numerous cases of irAEs have been reported, sequential multi-organ involvement, including progressive atopic dermatitis, vitiligo, autoimmune nephritis, autoimmune hepatitis, and autoimmune encephalitis after cessation of therapy, has not been previously documented.

Immunosuppression resulted in clinical remission of each irAE, highlighting the importance of vigilance for autoimmune complications in patients treated with checkpoint inhibition, even after immunotherapy cessation.

Shah, N., Jacob, J., Househ, Z., Shiner, E., Baird, L., and Soudy, H. Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab. 24093. 2019 J Immunother Cancer (7):1.

Concepts Keywords
Atopic Dermatitis Autoimmune encephalitis
Autoimmune Treatment malignant melanoma
Autoimmune Hepatitis Immunosuppression
Immunity Immunotherapy
Immunosuppression Medicine
Immunotherapy Clinical medicine
Malignant Melanoma Medical specialties
Melanoma Immune system
Nephritis Cancer treatments
Organ Immunology
Progressive Checkpoint inhibitor
Remission Antineoplastic drugs
Spectrum Breakthrough therapy
Toxicity Autoimmunity
Vitiligo Pembrolizumab
Immunotherapy

Semantics

Type Source Name
disease MESH complications
disease MESH autoimmune encephalitis
disease DOID autoimmune hepatitis
disease MESH autoimmune hepatitis
disease DOID nephritis
disease MESH nephritis
disease DOID vitiligo
disease MESH vitiligo
disease DOID atopic dermatitis
disease MESH atopic dermatitis
disease MESH multi
gene UNIPROT RPL17
pathway BSID Programmed Cell Death
pathway BSID Melanoma
disease DOID malignant melanoma
disease MESH malignant melanoma
drug DRUGBANK Pembrolizumab

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *